Evaluation of anti-SARS-CoV-2 antibody in patients with hematological diseases who receive treatment after vaccination.

Treatment for hematological diseases and its effect to anti-SARS-CoV-2 antibody. - Treatment for hematological diseases and its effect to anti-SARS-CoV-2 antibody.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052145

Enrollment

500

Registered

2023-09-07

Start date

2022-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with hematological diseases. 2) Patients who have received more than 3 times of vaccination before onset of hematological diseases. 3) Patients who will undergo treatment for hematological diseases. 4) Healthy volunteers who have received more than 3 times of vaccinationn and don' t receive immunosuppressive therapy.

Exclusion criteria

Exclusion criteria: Patients who are judged to be ineligible for the study.

Design outcomes

Primary

Measure	Time frame
Evaluation of anti-SARS-COV-2 antibody at baseline, 6m, 12m and 18m after treatment for hematological diseases.	—

Countries

Japan

Contacts

Public ContactTakeshi Kondo

Aiiku Hospital Blood Disorders Center

kondo@aiiku-hp.or.jp+81-11-563-2211

Outcome results